钆对比剂全程化药学服务共识

中国医药教育协会临床合理用药专业委员会; 广东省药学会用药评价与临床科研专家委员会; 王勇; 喻珊珊

doi:10.6039/j.issn.1001-0408.2023.17.01

您当前的位置：

首页 >

文章列表页 >

钆对比剂全程化药学服务共识

医药热点 | 更新时间：2023-09-14

- 钆对比剂全程化药学服务共识
- Consensus on whole-process pharmaceutical care for gadolinium-based contrast agents
- 中国药房 2023年34卷第17期页码：2049-2056
- 作者机构：
- 作者简介：
  
  王勇：教授，博士。研究方向：临床药学。电话：020-61643499。E-mail：yongwh2005@163.com
  喻珊珊：主任药师，博士。研究方向：临床药学。电话：020-61643549。E-mail：hygeia1019@163.com
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.17.01
  中图分类号： R981+.9
- 纸质出版日期：2023-09-15，
  
  收稿日期：2023-06-09，
  
  修回日期：2023-07-17，
扫描看全文
中国医药教育协会临床合理用药专业委员会,广东省药学会用药评价与临床科研专家委员会.钆对比剂全程化药学服务共识[J].中国药房,2023,34(17):2049-2056.

.Consensus on whole-process pharmaceutical care for gadolinium-based contrast agents[J].ZHONGGUO YAOFANG,2023,34(17):2049-2056.
中国医药教育协会临床合理用药专业委员会,广东省药学会用药评价与临床科研专家委员会.钆对比剂全程化药学服务共识[J].中国药房,2023,34(17):2049-2056. DOI： 10.6039/j.issn.1001-0408.2023.17.01.

.Consensus on whole-process pharmaceutical care for gadolinium-based contrast agents[J].ZHONGGUO YAOFANG,2023,34(17):2049-2056. DOI： 10.6039/j.issn.1001-0408.2023.17.01.

摘要

为促进钆对比剂的临床合理使用，并为医师处方该类对比剂及药师审核处方提供参考，本共识工作组根据国内外指南和共识，发起《钆对比剂全程化药学服务共识》编写项目。该项目由南方医科大学珠江医院牵头，联合国内多家医疗机构的临床专家和药学专家等，针对钆对比剂的基本药理作用、分类、药代动力学、药效动力学、适应证、禁忌证、注意事项、用法用量及不良反应等重点内容进行了研讨、总结，最终形成本共识。共识的主要内容包括各类钆对比剂的概述、临床合理使用、安全性管理及全程化药学服务流程等，供各级医疗机构医师、药师参考。

Abstract

In order to promote the rational clinical use of gadolinium-based contrast agents （GBCA） and to provide a reference for physicians to prescribe such contrast agents and for pharmacists to review prescriptions， the consensus working group launched the preparation project of “

Consensus on whole-process pharmaceutical care for GBCA

” according to domestic and foreign guidelines and consensus. The Zhujiang Hospital of Southern Medical University took the lead and cooperated with clinical experts and pharmaceutical experts from several domestic medical institutions to discuss and summarize the basic pharmacological effect of GBCA， types， pharmacokinetics， pharmacodynamics， indications， contraindications， precautions， usage and dosage， adverse drug reactions， and finally forms the consensus. The main contents of this consensus include an overview of various types of GBCA， rational clinical use of drugs， security management and whole-process pharmaceutical care process， etc.， for reference by physicians and pharmacists in medical institutions at all levels.

关键词

钆对比剂合理用药药物不良反应药学服务全流程共识

Keywords

rational drug useadverse drug reactionspharmaceutical carewhole-processconsensus

references

ACR Committee on Drugs and Contrast Media. ACR manual on contrast media[M]. 2021 edition. Washington：American College of Radiology，2021：75-78.

李坤成. 磁共振成像对比剂的临床应用[M]. 北京：人民卫生出版社，2016：1-10.

DO Q N，LENKINSKI R E，TIRCSO G，et al. How the chemical properties of GBCAs influence their safety profiles in vivo[J]. Molecules，2021，27（1）：58.

中华医学会放射学分会磁共振学组，中华医学会放射学分会质量控制与安全工作委员会. 钆对比剂临床安全性应用中国专家建议[J]. 中华放射学杂志，2019，53（7）：539-544.

COSTELLOE C M，AMINI B，MADEWELL J E. WITHDRAWN：risks and benefits of gadolinium-based contrast enhanced MRI[J]. Semin Ultrasound CT MR，2020，41（2）：260-274.

HUANG X X，JIANG R H，XU X Q，et al. Ischemic stroke increased gadolinium deposition in the brain and aggravated astrocyte injury after gadolinium-based contrast agent administration：linear versus macrocyclic agents[J]. J Magn Reson Imaging，2021，53（4）：1282-1292.

FATIMA A，AHMAD M W，AL SAIDI A K A，et al. Recent advances in gadolinium based contrast agents for bioimaging applications[J]. Nanomaterials，2021，11（9）：2449.

SHEN Y Q，GOERNER F L，SNYDER C，et al. T1 relaxi- vities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5，3，and 7 T[J]. Invest Radiol，2015，50（5）：330-338.

ROHRER M，BAUER H，MINTOROVITCH J，et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths[J]. Invest Radiol，2005，40（11）：715-724.

段二月，马建功，程鹏. 钆类造影剂的研究进展[J]. 大学化学，2016，31（7）：1-13.

Radiology European Society of Urogenital. ESUR guidelines on contrast agents[M]. Vienna：ESUR Guidelines on Contrast Agents，2018：6-35.

RONG D L，HE B J，TANG W J，et al. Comparison of gadobenate-enhanced MRI and gadoxetate-enhanced MRI for hepatocellular carcinoma detection using LI-RADS version 2018：a prospective intraindividual randomized study[J]. AJR Am J Roentgenol，2022，218（4）：687-698.

SOULEZ G，BLOOMGARDEN D C，ROFSKY N M，　　et al. Prospective cohort study of nephrogenic systemic fibrosis in patients with stage 3-5 chronic kidney disease undergoing MRI with injected gadobenate dimeglumine or gadoteridol[J]. AJR Am J Roentgenol，2015，205（3）：469-478.

WOOLEN S A，SHANKAR P R，GAGNIER J J，et al. Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group Ⅱ gadolinium-based contrast agent：a systematic review and meta-analysis[J]. JAMA Intern Med，2020，180（2）：223-230.

ATTARI H，CAO Y，ELMHOLDT T R，et al. A systematic review of 639 patients with biopsy-confirmed nephrogenic systemic fibrosis[J]. Radiology，2019，292（2）：376-386.

STAREKOVA J，BRUCE R J，SADOWSKI E A，et al. No cases of nephrogenic systemic fibrosis after administration of gadoxetic acid[J]. Radiology，2020，297（3）：556-562.

TSENG T Y，TSENG J H，HUANG B S，et al. Risk of nephrogenic systemic fibrosis in patients with impaired renal function undergoing fixed-dose gadoxetic acid-enhanced magnetic resonance imaging[J]. Abdom Radiol，2021，46（8）：3995-4001.

ROBERT P，VIVES V，GRINDEL A L，et al. Contrast-to-dose relationship of gadopiclenol，an MRI macrocyclic gadolinium-based contrast agent，compared with gado- terate，gadobenate，and gadobutrol in a rat brain tumor model[J]. Radiology，2020，294（1）：117-126.

ROBIC C，PORT M，ROUSSEAUX O，et al. Physicochemical and pharmacokinetic profiles of gadopiclenol：a new macrocyclic gadolinium chelate with high T1 relaxi- vity[J]. Invest Radiol，2019，54（8）：475-484.

LOEVNER L A，KOLUMBAN B，HUTÓCZKI G，et al. Efficacy and safety of gadopiclenol for contrast-enhanced MRI of the central nervous system：the PICTURE rando- mized clinical trial[J]. Invest Radiol，2023，58（5）：307-313.

中华医学会放射学分会质量控制与安全管理专业委员会. 肾病患者静脉注射钆对比剂应用中国专家共识[J]. 中华放射学杂志，2022，56（3）：221-230.

BEHZADI A H，ZHAO Y Z，FAROOQ Z，et al. Imme- diate allergic reactions to gadolinium-based contrast agents：a systematic review and meta-analysis[J]. Radiology，2018，286（2）：731.

耿雯瑾，赵月婷，曾贞，等. 肾源性系统性纤维化1例[J]. 中国皮肤性病学杂志，2020，34（10）：1170-1172.

MCDONALD R J，MCDONALD J S，KALLMES D F， et al. Intracranial gadolinium deposition after contrast-enhanced MR imaging[J]. Radiology，2015，275（3）：772-782.

MURATA N，GONZALEZ-CUYAR L F，MURATA K， et al. Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue：preliminary results from 9 patients with normal renal function[J]. Invest Radiol，2016，51（7）：447-453.

KANDA T，FUKUSATO T，MATSUDA M，et al. Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction：evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy[J]. Radiology，2015，276（1）：228-232.

MCDONALD R J，MCDONALD J S，DAI D Y，et al. Comparison of gadolinium concentrations within multiple rat organs after intravenous administration of linear versus macrocyclic gadolinium chelates[J]. Radiology，2017，285（2）：536-545.

JOST G，FRENZEL T，BOYKEN J，et al. Long-term excretion of gadolinium-based contrast agents：linear versus macrocyclic agents in an experimental rat model[J]. Radiology，2019，290（2）：340-348.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

碘对比剂全程化药学服务共识

对炎症性肠病患者开展抗TNF-α制剂TDM的国内外指南/共识的质量评价

基于临床治疗指南及共识的住院患者多黏菌素B应用分析与评价

上海市金山区居家严重精神障碍患者用药依从性影响因素及药物不良反应调查分析 ^Δ